Nuvectis Pharma, Inc.
NVCT· Nasdaq
Released Feb 11, 2026, before the open
10-K filed Feb 11, 2026, 42 days after period end · 0001104659-26-013044
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$7.31M | -$6.25M | -$6.62M | -$6.70M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nuvectis Pharma, Inc. · CIK 1875558 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2025 · filed Feb 11, 2026 · 42 d after period end
+0.2% from the close of Feb 10, 2026 to the close of Feb 11, 2026, the first after the release.